MOTS-c Traveling While on This Drug: A Practical Guide for Daily Life
HealthRX.com
No approved dose or storage rule exists for MOTS-c travel
Key numbers
- 5 mgStrength of one nominated MOTS-c injection product, which is not an approved doseSource: fda.gov, as cited Nov 7, 2026
- 10 mgStrength of the other nominated MOTS-c injection product, not an approved human doseSource: fda.gov, as cited Nov 7, 2026
- 0.5 to 15 mg/kgRodent doses in animal studies, which cannot be converted into a human doseSource: fda.gov, as cited Nov 7, 2026
At a glance
- FDA status / Not an approved drug, not a component of one [1]
- Approved dose / None; nominated products were 5 mg and 10 mg injections [1]
- Human pharmacokinetics / None in humans or live animals; rapid breakdown in blood in vitro [1]
- Storage instruction / No FDA-approved storage instruction exists [1]
- FDA compounding lists / Appears on none of FDA's lists for pharmacies or outsourcing facilities [3][4][5]
- Sport / Prohibited at all times under WADA S4.4.1 [6]
Is there an approved label or storage temperature to follow?
No. MOTS-c is not an FDA-approved drug and is not a component of one. FDA's July 2026 review found no USP or National Formulary monograph, no entry in the European or Japanese pharmacopeias and no EMA-authorised product [1]. Any instruction printed on a particular vial is not an FDA-approved product instruction.
What is known about MOTS-c in the body?
MOTS-c is a 16-amino-acid peptide encoded in mitochondrial DNA, first reported in 2015 [7]. The pharmacology comes from cells and rodents: in mice, injected MOTS-c prevented age-dependent and high-fat-diet-induced insulin resistance and diet-induced obesity [7].
In people, FDA found no pharmacokinetic data for MOTS-c in humans or live animals; the only kinetic observation is rapid breakdown in human blood in vitro [1]. FDA's searches of PubMed, Embase and the Cochrane library found no clinical study in which MOTS-c was given to a human, and its stated safety concern for injection is immunogenicity from aggregation and peptide-related impurities [1][2]. Adverse-event database searches through March 9, 2025 retrieved no MOTS-c reports [1].
Doses and missed doses on the road
There is no approved dose and no human dosing study of administered MOTS-c [1]. The nominated products were 5 mg and 10 mg subcutaneous injections, and rodent doses of 0.5 to 15 mg/kg cannot be converted into a human dose [1]. As a result, there is no evidence-based schedule to shift across time zones and no missed-dose rule.
Questions worth asking
Border and legal status
MOTS-c appears in none of the three categories on FDA's list for state-licensed pharmacies and physicians (updated May 14, 2026) and is absent from the outsourcing-facility list (updated March 21, 2025) [3][4][5]. It sits in the 'nominated but withdrawn' table on FDA's page about bulk substances that may present significant safety risks, and removal from category 2 was not a finding that it is safe [2].
FDA's Pharmacy Compounding Advisory Committee voted on July 23, 2026 in favor of adding MOTS-c to the list, against FDA staff's recommendation; the advice is non-binding [8][9]. A draft HHS policy filed October 28, 2026 names MOTS-c acetate for subcutaneous or intramuscular injection and states HHS does not intend enforcement action against certain pharmacies, federal facilities or physicians if its conditions are met; it is non-binding, not an approval and not a listing [9][10].
Traveling to compete
WADA's Prohibited List names MOTS-c in S4.4.1 among metabolic modulators, as an example of an AMPK activator, and prohibits it at all times, in and out of competition [6]. It is on the 2026 List and remains on the 2027 List [6][11].
Check what you know
Question 1 of 4
Score: 0 right, 0 of 4 answered
Frequently asked questions
Does MOTS-c need to be kept cold while traveling?
What should I do if I miss a dose while traveling?
Will MOTS-c help with jet lag or travel fatigue?
Can I compete in sport while using MOTS-c?
References
Show all 12 referencesHide references
- U.S. Food and Drug Administration.
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- Bulk Drug Substances Used in Compounding of the FD&C Act | FDA.
- World Anti-Doping Agency.
- Lee C, Zeng J, Drew BG, Sallam T, Martin-Montalvo A, Wan J, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443-54.
- U.S. Food and Drug Administration.
- Official web page.
- Official web page.
- World Anti-Doping Agency.
- von Walden F, Fernandez-Gonzalo R, Norrbom J, Emanuelsson EB, Figueiredo VC, Gidlund EK, et al. Acute endurance exercise stimulates circulating levels of mitochondrial-derived peptides in humans. J Appl Physiol (1985). 2021;131(3):1035-1042.